The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial release generated significant gains, the lapse of its patent opened the floodgates to generic versions, https://adsbookmark.com/story21749359/sildenafil-and-big-pharma-a-risky-investment